PNU 101017
Alternative Names: U 101017Latest Information Update: 06 Aug 2002
At a glance
- Originator Pharmacia Corporation
- Class Anxiolytics; Neuroprotectants; Quinolines; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Neurological disorders
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 17 Mar 1999 Phase-I clinical trials for Anxiety disorders in USA (Unknown route)
- 11 Nov 1997 Preclinical development for Neurological disorders in USA (Unknown route)